Filtered By:
Vaccination: Ebola Vaccine
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 607 results found since Jan 2013.
Addressing the Threat of Emerging Viral Infections
Keio J Med. 2023;72(1):27. doi: 10.2302/kjm.ABSTRACT_72_1-2.ABSTRACTEmerging infections are caused when microorganisms that are maintained in a reservoir where they cause no harm, transmit from the reservoir to a new host. I have been studying the replication, molecular basis for pathogenesis, and host responses to emerging viruses, including influenza virus, Ebola virus, and SARS-CoV-2, and using the knowledge gained from these studies to develop antivirals and vaccines.Influenza viruses cause epidemics every winter, but occasionally new influenza viruses emerge and spread worldwide (pandemic). We established a technique ...
Source: The Keio Journal of Medicine - March 26, 2023 Category: Universities & Medical Training Authors: Yoshihiro Kawaoka Source Type: research
Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSV ΔG-ZEBOV-GP)
Vaccine. 2023 Jan 30:S0264-410X(23)00090-7. doi: 10.1016/j.vaccine.2023.01.059. Online ahead of print.ABSTRACTWhile effective at preventing Zaire ebolavirus (ZEBOV) disease, cellular immunity to ZEBOV and vector-directed immunity elicited by the recombinant vesicular stomatitis virus expressing ZEBOV glycoprotein (rVSVΔG-ZEBOV-GP) vaccine remain poorly understood. Sera and peripheral blood mononuclear cells were collected from 32 participants enrolled in a prospective multicenter study [ClinicalTrials.gov NCT02788227] before vaccination and up to six months post-vaccination. IgM and IgG antibodies, IgG-producing memory B ...
Source: Vaccine - February 1, 2023 Category: Allergy & Immunology Authors: Vanessa Raabe Lilin Lai Juliet Morales Yongxian Xu Nadine Rouphael Richard T Davey Mark J Mulligan Source Type: research
Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections
Mol Biotechnol. 2023 Jan 31. doi: 10.1007/s12033-023-00679-1. Online ahead of print.ABSTRACTNovel effective drugs or therapeutic vaccines have been already developed to eradicate viral infections. Some non-viral carriers have been used for effective drug delivery to a target cell or tissue. Among them, cell penetrating peptides (CPPs) attracted a special interest to enhance drug delivery into the cells with low toxicity. They were also applied to transfer peptide/protein-based and nucleic acids-based therapeutic vaccines against viral infections. CPPs-conjugated drugs or vaccines were investigated in several viral infectio...
Source: Herpes - January 31, 2023 Category: Infectious Diseases Authors: Niloofar Khairkhah Ali Namvar Azam Bolhassani Source Type: research
Structure of the Inmazeb cocktail and resistance to Ebola virus escape
Cell Host Microbe. 2023 Jan 20:S1931-3128(23)00022-7. doi: 10.1016/j.chom.2023.01.002. Online ahead of print.ABSTRACTMonoclonal antibodies can provide important pre- or post-exposure protection against infectious disease for those not yet vaccinated or in individuals that fail to mount a protective immune response after vaccination. Inmazeb (REGN-EB3), a three-antibody cocktail against Ebola virus, lessened disease and improved survival in a controlled trial. Here, we present the cryo-EM structure at 3.1 Å of the Ebola virus glycoprotein, determined without symmetry averaging, in a simultaneous complex with the antibodies...
Source: Cell Host and Microbe - January 28, 2023 Category: Microbiology Authors: Vamseedhar Rayaprolu Benjamin O Fulton Ashique Rafique Emilia Arturo Dewight Williams Chitra Hariharan Heather Callaway Amar Parvate Sharon L Schendel Diptiben Parekh Sean Hui Kelly Shaffer Kristen E Pascal Elzbieta Wloga Stephanie Giordano Nicole Negron Source Type: research
